Hurdles Hindering the Translation of AI-Powered Research into Tangible Clinical Benefits

Estimated read time 1 min read

In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses why no novel active substances have yet been brought to market through AI technology despite increasing investments in the space for drug discovery as shown in IQVIA’s Global Trends in R&D 2024 report.

You May Also Like

More From Author

+ There are no comments

Add yours